Is MS an inflammatory or primary degenerative disease? by Jacek Losy
NEUROLOGY AND PRECLINICAL NEUROLOGICAL STUDIES - CONY PRO/CON DEBATE
Is MS an inflammatory or primary degenerative disease?
Jacek Losy
Received: 13 July 2012 / Accepted: 2 August 2013 / Published online: 6 September 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract Multiple sclerosis (MS) is characterized by
multiple areas of inflammation, demyelination and neuro-
degeneration. Multiple molecular and cellular components
mediate neuroinflammation in MS. They involve: adhesion
molecules, chemokines, cytokines, matalloproteases and
the following cells: CD4? T cells, CD8? T cells, B cells,
microglia and macrophages. Infiltrating Th1 CD4? T cells
secrete proinflammatory cytokines. They stimulate the
release of chemokines, expression of adhesion molecules
and can be factors that cause damage to the myelin sheath
and axons. Chemokines stimulate integrin activation,
mediate leukocyte locomotion on endothelial cells and
participate in transendothelial migration. CD8? cells can
directly damage axons. B cells are involved in the pro-
duction of antibodies which can participate in demyelina-
tion. B cells can also function as antigen presenting cells
and contribute to T cell activation. Neuroinflammation is
not only present in relapsing–remitting MS, but also in the
secondary and primary progressive forms of the disease.
The association between inflammation consisting of T
cells, B cells, plasma cells and macrophages and axonal
injury exists in MS patients including the progressive forms
of the disease. The above association does not exclude the
possibility that neurodegeneration can exist independently
from inflammation. Very little inflammation is seen in
cortical MS plaques. Anti-inflammatory therapies with
different mode of action change the course of MS. Anti-
inflammatory and immunomodulatory treatments are ben-
eficial in the early relapsing stage of MS, but these treat-
ments are ineffective in secondary progressive and primary
progressive MS. In the stage of progressive MS, inflam-
mation becomes trapped behind a closed or repaired blood–
brain barrier. In such a situation current immunomodula-
tory, immunosuppressive or anti-inflammatory treatments
might not reach this inflammatory process to exert a ben-
eficial effect.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory disease
of the central nervous system, which leads to the devel-
opment of focal inflammatory lesions with secondary
axonal damage. This concept has recently been challenged
by several observations, suggesting that in MS neurode-
generation may occur independently of inflammation.
More radical view suggests that the primary process in MS
is neurodegeneration augmented by a secondary inflam-
matory reaction. Are there any arguments for this concept?
In contrast to white matter lesions, very little inflam-
mation is seen in cortical MS plaques (Lassmann 2010).
This could suggest that cortical demyelination can develop
independently from inflammation. However, it is also
evident that cortical demyelination occurs in association
with profound meningeal inflammation (Kutzeinigg et al.
2005). Soluble inflammatory factors from these cells can
diffuse into the cortical tissue and destroy myelin. Another
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presented argument for the independence of neurodegen-
eration from inflammation is that treatments targeting
inflammation are only effective in relapsing type of the
disease, being largely ineffective in progressive forms of
MS. Possible explanation of that will be discussed later in
this paper.
Inflammation in multiple sclerosis appears as a crucial
multi-step process beginning with peripheral immune
reactions creating autoreactive T cells, transmigration of
immune cells through blood–brain barrier, followed by
demyelination, degeneration and axonal damage in the
white and gray matter.
Peripheral inflammatory reactions
The exact factors that initiate inflammation in MS are
unknown, but it is generally accepted that environmental
factors play an important role in genetically susceptible
individuals triggering T cell mediated response against
CNS. Myelin-specific activated autoreactive T cells are
found in the peripheral blood of MS patients. Molecular
mimicry mechanism in which T cells generated against non
self, viral or microbial epitopes, cross react with self
myelin epitopes of the similar sequence has been postu-
lated as a potential autoimmune mechanism (Comabella
and Khoury 2012). There are several genes that confer
susceptibility to MS. Among the most important are genes
of the major histocompatibility complex like
HLADRB1*1501 allele, HLA DQA1*0102 allele or HLA
DQB1*0602 allele, responsible for about 50 % genetic risk
for MS. It has also been found that HLA DRB1 1501 allele
is linked to disease severity. Other genes, which have been
identified code for receptors of interleukin 2 and interleu-
kin 7.
Migration of inflammatory cells to the CNS
The leukocyte trafficking to the brain of MS patients is a
complex process (Rubenko-Moll et al. 2006). It is initiated
by tethering and rolling of the leukocytes on endothelial
surfaces, mediated by endothelial selectins which interact
with glycosylated ligands on the leukocytes. The L, E, and
P selectins participate in this process.
A significant increase in soluble forms of selectins has
been found in the sera of patients with relapsing–remitting
MS and correlated with disease activity (Losy 1999; Kuenz
et al. 2005).
The rolling leukocytes interact with chemokines, which
are immobilized on endothelium, and bind to their recep-
tors on leukocytes. The chemokine receptors activation
results in G-protein signal and the activation of leukocyte
integrins changing their state from low to high affinity/
avidity. The activated integrins interact with their endo-
thelial counter-receptors of the immunoglobulin super-
family. Among the most important are: the b2 integrin
leukocyte function associated antigen (LFA-1) binding to
ICAM-1 and the a4b1 integrin very late antigen-4 (VLA-4)
binding to VCAM-1. These interactions result in leukocyte
arrest and adhesion on the endothelial surface. Increased
soluble ICAM-1 levels have been found in the CSF and
sera of MS patients and correlated with disease activity
(Hartung et al. 1993). Elevated concentrations of sVCAM-
1 in the CSF and sera have also been found in MS patients
(Droogan and McMillan 1996). The correlation between
sVCAM-1 and gadolinium enhancement in MRI has been
shown (Hartung et al. 1995).
Another important adhesion molecule is the platelet
endothelial cell adhesion molecule-1 (PECAM-1) (Wood-
fin et al. 2007). The expression of PECAM-1 on endothe-
lial cells is concentrated at cell to cell junctions. PECAM-1
binds to itself and also to leukocyte avb3 integrin, an
adhesion molecule found on endothelial cells and NK cells.
The process of migration through intercellular junctions of
vascular endothelial cells is mediated by homophilic
adhesive interactions that take place between leukocyte and
endothelial cell junctional PECAM-1 molecules. Increased
levels of sPECAM-1 have been detected in serum and CSF
of patients with active, gadolinium enhancing MS lesions
on MRI (Losy et al. 1999).
Following leukocyte arrest, in the locomotion phase of
the process the leukocytes travel across endothelial sur-
faces in search of interendothelial junctions. After protru-
sion, transmigration occurs in response to the abluminal
chemokines according to the chemotactic gradient. Next,
the leukocytes penetrate across the endothelial basement
membrane to the perivascular space. Entry into the brain
parenchyma needs a transversing of the glia limitans and its
associated basement membrane which requires the action
of matrix matalloproteases. The association between spe-
cific MMP serum levels, clinical and MRI activity has been
observed in MS patients (Helgeland and Gilhus 2012).
Different pairs of chemokine receptors and their ligands
play a pathogenic role in MS. Chemokines stimulate inte-
grin activation, mediate leukocyte locomotion on endo-
thelial cells and participate in transendothelial migration
according to chemoattractant gradients. The CXCR3
receptor is expressed on the majority of T cells in the CSF
of patients with MS. CXCL9 and CXCL10, CXCR3
receptor ligands were elevated in the CSF of patients with
MS during relapse. These chemokines were also detected
in actively demyelinating lesions. CXCL12 and CXCL13
are crucial for B cell trafficking to the CNS. Both che-
mokines have been found to be elevated in the CSF of
patients with MS and demyelinating lesions (Krumbholtz
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et al. 2006). CX3CR1 participates in NK cell migration to
the CNS. It has been shown that these cells correlate with
disease activity in MS patients (Infante-Duarte et al. 2005).
Involvement of inflammatory cells in demyelination
and neurodegeneration
Inflammatory pathogenic T cells, which enter the CNS
initiate a complex immunological cascade consisting of
epitope spreading, which triggers new attacks and activa-
tion of the innate immune system consisting of microglia,
dendritic cells, astrocytes and B cells which leads to
chronic CNS inflammation (Weiner 2009).
Infiltrating cells secrete proinflammatory cytokines like
IFN-c, TNF-a, IL-2. Another important cytokine playing a
significant role in MS is IL-18, stimulating the release of
IFN-c (Losy and Niezgoda 2001). Proinflammatory cyto-
kines stimulate the release of chemokines, expression of
adhesion molecules and can be factors damaging both
myelin sheath and axons. Th2 CD4? cells release anti-
inflammatory cytokines having an immunomodulatory
effect. The regulatory T cells (CD4? CD25? Treg) are a
small subset of CD4? T cells. Defects in functional sup-
pression by these cells in MS patients has been described
(Viglietta et al. 2004).
Th17 cells are also participating in MS neuroinflam-
mation. These cells release the proinflammatory cytokine
IL-17. It has been shown that IL 23 produced by macro-
phages and dendritic cells is important for the expansion of
Th17 cells (Korn et al. 2009). Th 17 cells in the CSF of MS
patients are significantly increased during exacerbations in
comparison with remission periods (Brucklacher-Waldert
et al. 2009).
CD8? cells are also involved in inflammatory reaction
and correlate better with axon destruction in demyelinating
lesions than CD4? cells (Bitsch et al. 2002). CD8? cells
can directly damage axons or this damage can follow the
destruction of the myelin sheath and oligodendrocytes
(Melzer et al. 2009).These cells may transect neuritis in an
MHC class I/peptide-restricted fashion. The mechanism of
axonal damage is multifactorial and includes also action of
proteases and free radicals released during CNS inflam-
mation as well as lack of neurotrophic factors provided to
axons (Comabella and Khoury 2012). B cells stimulated by
IL-4, IL-6 and IL-10 are involved in the production of
antibodies which can participate in demyelination in the
form of immune complexes which activate complement or
participate in antibody dependent cell cytotoxicity. B cells
have also the capacity to function as antigen presenting cells
and contribute to T cell activation (Barun and Bar-Or 2012).
Neuroinflammation is not only present in relapsing–
remitting multiple sclerosis but also in the secondary and
primary progressive forms of the disease. T and B cell
infiltrates correlate well with the activity of demyelinating
lesions, while plasma cells seem to be most pronounced in
patients with secondary and primary progressive MS. A
highly significant association between inflammation con-
sisting of T cells, B cells, plasma cells and macrophages
and axonal injury exists in MS patients including pro-
gressive forms of the disease alone (Frischer et al. 2009).
The effect of immunomodulating, anti-inflammatory
therapies
Anti-inflammatory therapies with a different mode of
action influence the disease course. Natalizumab which is a
monoclonal antibody against VLA-4 integrin, interfering
with the process of leukocytes adhesion to endothelium,
reduces significantly the relapse rate, the risk of disability
progression and MRI activity (Polman et al. 2006).
Alemtuzumab causing prolonged depletion of peripheral
blood lymphocytes shows better results in comparison with
IFN-b 1a in the reduction of the relapse rate and the risk for
sustained disability.
Rituximab a chimeric antibody against CD20 on B cells
has shown a reduction in MRI activity and a reduction of
the relapse rate (Hauser et al. 2009). Another monoclonal
antibody, daclizumab, directed against the a subunit
(CD25) of IL-2 receptor inhibits activated T cells. It can
also cause an expansion of the subset of NK cells, CD56
bright cells, which lyse autologous T cells. Added to
treatment with interferon b 1a reduced significantly the
MRI activity of MS patients (Wynn et al. 2010).
Several oral new dugs have also anti-inflammatory
properties and affect clinical and MRI activity in MS
patients. Fingolimod, sphingosine-1-phosphate receptor
modulator reversibly sequesters lymphocytes mainly in the
lymph nodes, reducing their recirculation to the CNS and
abrogating the neuroinflammatory process (Kappos et al.
2006). It has been also shown to suppress the generation of
Th17 cells in vitro (Liao et al. 2007). Triflunomide blocks
lymphocyte T and B proliferation by inhibiting dehydro-
orotate dehydrogenase (DHODH), a key enzyme needed
for pyrimidine synthesis (O´ Connor et al. 2006). Dimethyl
fumarate (BG-12) induces a shift from Th1 (proinflam-
matory) to Th2 (anti-inflammatory) cytokine response. It
decreases also the expression of ICAM-1 and VCAM-1
(De-Hyung Lee et al. 2008). It is now established that anti-
inflammatory and immunomodulatory treatment is benefi-
cial in the early relapsing stage of MS, but these treatments
are ineffective in secondary progressive and particularly in
primary progressive MS. Is this a proof for the indepen-
dence of neurodegeneration from the inflammatory pro-
cess? Not necessarily. In the stage of progressive MS,
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inflammation becomes trapped behind a closed or repaired
blood–brain barrier (Lassmann 2010). In such a situation
current immunomodulatory, immunosuppressive or anti-
inflammatory treatments might not reach this inflammatory
process in concentrations which are sufficient to exert a
beneficial effect. Neurodegeneration caused by inflamma-
tion in earlier stages of the disease is dominant in later
stages of MS and requires neuroprotective and neurore-
generation treatment strategies.
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